source
- Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapyNovo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.